Results 61 to 70 of about 50,964 (281)

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Systemic treatment for metastatic prostate cancer

Asian Journal of Urology, 2019
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy ...
Gwenaelle Gravis
doaj   +1 more source

Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis

Advanced Science, EarlyView.
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu, Qiu Peng, Xiaoyue Zhang, Zhengshuo Li, Yangge Wu, Yuqing Wen, Run Zheng, Shuanglong Wu, Chenfei Zhou, Zhengyu Hu, Lanjun Shu, Xinyi Ma, Qiuyang Li, Ya Ma, Chunlin Ou, Ming Zhao, Songqing Fan, Lingyu Wei, Jian Ma   +18 more
wiley   +1 more source

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide [PDF]

, 2013
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate ...
Joelle El-Amm, Jeanny B. Aragon-Ching, Nihar Patel, El-Amm, Joelle, Patel, Nihar, Aragon-Ching, Jeanny B., Ashley Freeman, Freeman, Ashley   +7 more
core   +1 more source

ANXA2‐mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

Advanced Science, EarlyView.
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo, Tianlong Luo, Lingfeng Li, Qi Sun, Dongquan Li, Shanhe Huang, Zonglin Li, Weilong Lin, Yuan Ou, Tao Du, Shengmeng Peng, Kewei Xu, Bisheng Cheng, Hai Huang   +13 more
wiley   +1 more source

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

, 2018
Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required.
Crespo, M, Sharp, A, Francis, JC, Plymate, SR, Swain, A, Carreira, S, Nava Rodrigues, D, de Bono, JS, Paschalis, A, Ning, J, Sumanasuriya, S, Hughes, A, Gil, V, International SU2C/PCF Prostate Cancer Dream Team,, Seed, G, Chinnaiyan, AM, Yuan, W, Dolling, D, Neeb, A, Knight, E, Mani, RS, Raj, GV, Figueiredo, I, Welti, J, Clarke, M, Boysen, G, Halsey, WS   +26 more
core   +1 more source

Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment [PDF]

, 2004
Objective To establish which attributes of conservative treatments for prostate cancer are most important to men. Design Discrete choice experiment. Setting Two London hospitals. Participants 129 men with non-metastatic prostate cancer, mean age 70 years;
Bryan, S., De Winter, P, Payne, H, Sculpher, MJ, Fry, P., Emberton, M., Sculpher, M, Payne, H., Emberton, M, Bryan, Stirling, Sculpher, M., de Winter, P., Bryan, S, Fry, P   +13 more
core   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

Therapeutic Advances in Medical Oncology, 2017
Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy.
Naoki Terada, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Osamu Ogawa, Emmanuel S Antonarakis   +5 more
doaj   +1 more source

Castration-resistant prostate cancer: systemic therapy in 2012

Clinics, 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease
Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn   +2 more
doaj   +1 more source